CANTON BIOTECHNOLOGIES, INC.

Medtech · Private

Plasmid DNA delivery device using iontophoresis to transfect wound tissue and promote healing of diabetic foot ulcers

Grants
$190K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$149K
1 award · Defense
#490 of 4531 in medtech
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Defense · Phase I$149,343
Federal grantDepartment of Health and Human Services · Phase I · Development of Iontophoresis Device for Plasmid DNA Transfection of Hypoxia Inducible Factor-1 to Improve Wound Healing$149,772
Federal grantDepartment of Health and Human Services · Phase I · Development of Iontophoresis Device for Plasmid DNA Transfection of Hypoxia Inducible Factor-1 to Improve Wound Healing$40,000
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
487SOFTSONICS LLC$150K—
488Perfuzia Medical$150K—
489Cytoimage Inc.$150K$225K
490CANTON BIOTECHNOLOGIES, INC.$149K—
491Awarables, Inc.$149K$500K
492CND LIFE SCIENCES, INC.$146K$19M
493Vicis, Inc.$141K$67M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.